The third quarter of 2025 delivered key regulatory approvals, fresh clinical trial data, and important updates in GI care:
- AGA Gastroparesis Guideline (Sept 19, 2025)
The American Gastroenterological Association released a new clinical practice guideline with 12 conditional recommendations for diagnosing and managing gastroparesis. It underscores unmet needs and outlines evidence-based pharmacologic and procedural interventions. - FDA Approves Guselkumab (Tremfya) for UC
The FDA cleared a subcutaneous (SC) induction regimen of guselkumab for adults with moderately to severely active ulcerative colitis—making it the first IL-23 inhibitor with both SC and IV induction options for UC and Crohn’s disease. - GALAXI Trial Findings
New results from the GALAXI program highlighted guselkumab’s role in Crohn’s disease, offering clinicians insight into how the IL-23p19 inhibitor could reshape treatment strategies. - Obefazimod (ABX464) Phase 3 Success
Abivax announced positive topline results from its ABTECT-1 and ABTECT-2 induction trials. Obefazimod met the primary endpoint of clinical remission at week 8 for UC patients on a 50 mg once-daily regimen. - IBS: New Approaches, Ongoing Challenges
A 9-week phone-delivered psychological intervention (WISH) showed promise for IBS outcomes, while the IBS in America survey revealed symptoms still significantly impact daily life and productivity despite treatment advances.